Avaleht/Aktsiad/MOLN

MOLN

USD

Molecular Partners AG American Depositary Shares

$3.910-0.200 (-4.868%)

Reaalajas hind

Healthcare

Biotehnoloogia

Šveits

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad

Ettevõtte fundamentaalnäitajad

Kauplemisstatistika

Turunäitajad

Avatud

$4.110

Kõrge

$4.265

Madal

$3.720

Maht

0.01M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

146.2M

Tööstusharu

Biotehnoloogia

Riik

Switzerland

Kauplemisstatistika

Keskmine maht

0.00M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $3.36Praegune $3.910Kõrge $6.24

Seotud uudised

3. nov 2025 · 06:00

GlobeNewswire

Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025

Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell cytotoxicity against cells co-expressing

Vaata rohkem

Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025

3. nov 2025 · 06:00

GlobeNewswire

Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company

Vaata rohkem

Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting

30. okt 2025 · 20:00

GlobeNewswire

Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

IND application filed for MP0712, the Company's lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025 First patient images from MP0712

Vaata rohkem